EBS vs. JNJ, BCRX, CLDX, INVA, NVAX, DVAX, MNKD, OPK, GERN, and RIGL
Should you be buying Emergent Biosolutions stock or one of its competitors? The main competitors of Emergent Biosolutions include Johnson & Johnson (JNJ), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "medical" sector.
Emergent Biosolutions vs. Its Competitors
Johnson & Johnson (NYSE:JNJ) and Emergent Biosolutions (NYSE:EBS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.
Johnson & Johnson has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.
69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Comparatively, 1.2% of Emergent Biosolutions shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Johnson & Johnson presently has a consensus target price of $176.29, indicating a potential upside of 0.49%. Emergent Biosolutions has a consensus target price of $14.33, indicating a potential upside of 69.83%. Given Emergent Biosolutions' stronger consensus rating and higher probable upside, analysts plainly believe Emergent Biosolutions is more favorable than Johnson & Johnson.
In the previous week, Johnson & Johnson had 74 more articles in the media than Emergent Biosolutions. MarketBeat recorded 79 mentions for Johnson & Johnson and 5 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.24 beat Emergent Biosolutions' score of 0.64 indicating that Johnson & Johnson is being referred to more favorably in the media.
Johnson & Johnson has a net margin of 25.00% compared to Emergent Biosolutions' net margin of 16.38%. Johnson & Johnson's return on equity of 32.49% beat Emergent Biosolutions' return on equity.
Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Summary
Johnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks.
Get Emergent Biosolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent Biosolutions Competitors List
Related Companies and Tools
This page (NYSE:EBS) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access